Lobna Shalaby
- Clinical Biochemistry top 10%
- Bacterial Identification and Susceptibility Testing 6
- Molecular Medicine top 10%
- Antibiotic Resistance in Bacteria 5
-
- Neutropenia and Cancer Infections 11
-
- Fungal Infections and Studies 4
-
- Childhood Cancer Survivors' Quality of Life 5
-
- Antifungal resistance and susceptibility 4
-
- Acute Lymphoblastic Leukemia research 4
-
- Antibiotics Pharmacokinetics and Efficacy 4
Lobna Shalaby
27 papers receiving 269 citations
Peers
Comparison fields: 5 of 61
- Clinical Biochemistry 66
- Molecular Medicine 39
- Oncology 130
- Applied Microbiology and Biotechnology 6
- Epidemiology 93
Countries citing papers authored by Lobna Shalaby
This map shows the geographic impact of Lobna Shalaby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lobna Shalaby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lobna Shalaby more than expected).
Fields of papers citing papers by Lobna Shalaby
This network shows the impact of papers produced by Lobna Shalaby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lobna Shalaby. The network helps show where Lobna Shalaby may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lobna Shalaby, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 0 | |
| 5 | 2023 | 7 | |
| 6 | 2022 | 0 | |
| 7 | 2022 | 1 | |
| 8 | 2022 | 1 | |
| 9 | 2021 | 4 | |
| 10 | 2020 | 3 | |
| 11 | 2020 | 14 | |
| 12 | 2019 | 3 | |
| 13 | 2019 | 1 | |
| 14 | 2017 | 4 | |
| 15 | 2015 | 12 | |
| 16 | 2015 | 24 | |
| 17 | 2015 | 13 | |
| 18 | 2010 | 64 | |
| 19 | 2007 | 46 | |
| 20 | 2005 | 2 |
About Lobna Shalaby
Lobna Shalaby is a scholar working on Molecular Medicine, Clinical Biochemistry and Oncology, having authored 30 papers that have together received 278 indexed citations. Recurring topics across this work include Neutropenia and Cancer Infections (11 papers), Bacterial Identification and Susceptibility Testing (6 papers), Childhood Cancer Survivors' Quality of Life (5 papers), Antibiotic Resistance in Bacteria (5 papers), Antifungal resistance and susceptibility (4 papers), Acute Lymphoblastic Leukemia research (4 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Fungal Infections and Studies (4 papers). The work is most often cited by research in Clinical Biochemistry (66 citations), Molecular Medicine (39 citations) and Oncology (130 citations). Lobna Shalaby has collaborated with scholars based in Egypt, United States and Saudi Arabia. Frequent co-authors include Hadir A. El‐Mahallawy, Manar M. Moneer, Hanafy Hafez, Hala Mounir Agha, Mohamed Hashem, Reham Khedr, Hala Taha, Reem Hassan, Asim Belgaumi and Mahmoud Hammad. Their work appears in journals such as Blood, Scientific Reports and International Journal of Molecular Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.